Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02053246 · ClinicalTrials.gov registry record · Phase 4
Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure
A Phase 4 study, sponsored by University of Florida.
- Terminated
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
NCT02053246: Clinical Trial Phase 4 study, sponsored by University of Florida.
NCT02053246 is a Phase 4 study that was terminated before completion, run by University of Florida. The registered enrollment target is 11 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02053246, a Phase 4 study, was terminated before completion, sponsored by University of Florida.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
Study Summary
Heart failure with preserved ejection fraction (HFpEF), is one of the leading causes of pulmonary hypertension (PH). Despite the severity of this disease, no established treatments exist for this class of PH. Nebivolol is a drug used in high blood pressure and heart failure, but not used in patients with PH. Due to some additional properties it possesses, the investigators believe nebivolol will improve disease severity in patients with PH associated with HFpEF. The hypothesis of this research study is that nebivolol improves PH severity in patients with HFpEF, as measured by hemodynamic and clinical parameters.
Primary Outcome
Difference between baseline and 18 week mean pulmonary artery pressure and pulmonary artery wedge pressure
Interventions
- DRUG Nebivolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2014-01 |
| Est. Completion | 2021-03 |
| Phase | Phase 4 |
Why NCT02053246 stopped before completion
NCT02053246 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Nebivolol is the first listed.
NCT02053246 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02053246 about?
NCT02053246 is a clinical study titled "Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure". Heart failure with preserved ejection fraction (HFpEF), is one of the leading causes of pulmonary hypertension (PH). Despite the severity of this disease, no established treatments exist for this class of PH. Nebivolol is a drug used in high blood pressure and heart failure, but not used in patients...
What is the current status of trial NCT02053246?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2014-01. Estimated completion is 2021-03.
What interventions are being tested in trial NCT02053246?
The interventions under investigation include: Nebivolol (DRUG).
Who is sponsoring clinical trial NCT02053246?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02053246's enrollment target sits among peer trials
11 1931st of 2000 higher than 61 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia